Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

E-ISSN： 1873-4286|19|3|366-376

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.3, 2013-01, pp. : 366-376

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effectiveness of Hsp90 Inhibitors as Anti-Cancer Drugs

Mini Reviews in Medicinal Chemistry, Vol. 6, Iss. 10, 2006-10 ,pp. : 1137-1143

Bentham Science Publishers

Access to resources Recommend Favorite

Possible Effects of Early Treatments of Hsp90 Inhibitors on Preventing the Evolution of Drug Resistance to Other Anti-Cancer Drugs

Current Medicinal Chemistry, Vol. 14, Iss. 2, 2007-01 ,pp. : 223-232

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 14, 2013-12 ,pp. : 1999-2013

Bentham Science Publishers

Access to resources Recommend Favorite

The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors

Current Cancer Drug Targets, Vol. 3, Iss. 5, 2003-10 ,pp. : 349-358

Bentham Science Publishers

Access to resources Recommend Favorite

Update on Hsp90 Inhibitors in Clinical Trial

Current Topics in Medicinal Chemistry, Vol. 9, Iss. 15, 2009-11 ,pp. : 1479-1492

Bentham Science Publishers

Access to resources Recommend Favorite